Happy holidays from our team to yours. 

Hope you're spending time with the people who matter most. We'll keep watching the markets while you enjoy the week.

Gold just hit fresh record highs. Tech analysts are calling for a 20% rally. Elon Musk hit $700 billion in wealth. And drug prices are dropping as much as 95%. 

Here's what happened this weekend while you were wrapping presents.

Gold: New Record Highs

Gold hit a new high, $4,452 per ounce. That's a record. 

Not just any record, the highest price ever. And silver joined the party, reaching $69. 

Gold is up 67% this year. That's the biggest yearly gain since 1979. Put another way, if you had $10,000 in gold at the start of 2025, you'd have about $16,700 now.

Why's everyone piling into gold right now? Two big reasons.

First, the Fed keeps cutting interest rates. Markets think we'll see two more cuts in 2026. When rates fall, gold becomes more attractive. You're not losing out on interest payments anymore.

Second, uncertainty sells gold. There's tension in Venezuela. Ukraine conflict continues. Trade worries persist. When people get nervous, they buy gold. It's that simple.

Key Points:

  • Gold: $4,452 (new record)

  • Silver: $69 (also a record)

  • Up 67% in 2025, best year since '79

  • Copper heads toward $12,000

Login or Subscribe to participate

Tech's 2026 Playbook Takes Shape

Dan Ives just dropped his predictions for 2026. And they're bold.

He thinks tech stocks could climb 20% in 2026. That's on top of this year's gains. His logic? We're still in the early innings of the AI revolution.

Here's what Ives sees coming:

Apple and Google team up. They'll announce a formal AI partnership around Google's Gemini platform. This could push Apple to a $5 trillion market cap. That partnership would give Apple a real AI strategy and potentially launch as a subscription service.

Tesla launches robotaxis in 30+ cities. Ives believes Tesla will start mass production of their Cybercab fleet. He sees the stock rising 26% in his base case, potentially 68% if everything goes right.

Microsoft dominates enterprise AI. Companies are moving fast to adopt AI through Azure. Microsoft's positioned to win that race.

The AI story is priced in. You're paying for the future, not the present.

Key Points:

  • Tech stocks predicted to rise 20% in 2026

  • Apple-Google AI partnership expected

  • Tesla robotaxis launching in 30+ cities

  • Microsoft winning enterprise AI adoption

Login or Subscribe to participate

Musk's Historic Week

Two big Musk headlines hit this week.

The Starlink Patent: Tesla filed a patent for car roofs made from special polymers. These materials let satellite signals pass through. Translation? Tesla's working on factory-installed Starlink internet for your car.

No more dead zones on road trips. No cellular coverage issues in rural areas. Just constant connectivity from space. The patent doesn't mention Starlink by name, but come on. It's obvious.This makes sense for Tesla's robotaxi plans

The $700 Billion Milestone: Musk became the first person ever to hit $700 billion in net worth. His fortune reached $749 billion after a Delaware court ruling.

Key Points:

  • Tesla patent hints at Starlink integration in cars

  • Roof design allows satellite signals through

  • Musk hits $700 billion net worth (first ever)

  • Court restored $139 billion Tesla pay package

Healthcare Gets a Price Tag

The Trump administration made two moves on healthcare costs.

Price Transparency Update: New rules proposed Friday would force hospitals and insurers to show actual prices—not estimates. The data needs to be easy to compare across providers.

They're also reducing reporting from monthly to quarterly. That cuts the burden but keeps transparency. 

The goal? Let you shop for healthcare like you shop for anything else. Compare prices. Choose the best value. Save money. 

One analysis estimates these rules could save $80 billion for consumers and employers.

Drugmakers Lower Prices: Nine major pharmaceutical companies agreed to cut drug prices this week. Merck, Bristol Myers Squibb, Amgen, Gilead, GSK, Sanofi, Genentech, Novartis, and Boehringer Ingelheim all signed on.

Some examples of the cuts:

  • Gilead's hepatitis C drug: $24,920 → $2,425

  • Bristol Myers Squibb's HIV medication: $1,449 → $217

  • Sanofi's blood thinner: $756 → $16

These prices will be available through TrumpRx.gov starting in January. The site lets you buy directly from manufacturers. Fourteen companies total have now signed price-reduction deals.

Key Points:

  • New transparency rules require actual prices 

  • Data must be comparable across hospitals/insurers

  • 9 drugmakers agreed to slash prices

  • Some drugs dropping 85-95% on TrumpRx

Will healthcare price transparency help you personally?

Login or Subscribe to participate

Bottom Line

This weekend's stories share a common thread: big changes, uncertain outcomes.

Gold's breaking records. Tech's betting billions on AI that hasn't fully proven itself yet. Musk's building his empire across cars, space, and satellites. Healthcare's finally getting price tags.

For your portfolio, here's what matters. Don't chase records just because they're records. Gold at $4,400 isn't automatically better than gold at $4,000. High prices cut both ways.

On tech, remember the P/E ratios. You're paying for tomorrow's earnings, not today's. That works great until it doesn't.

And on healthcare? Watch those price transparency rules. If they work, they could actually move the needle on your medical costs. That's real money.

Stay smart out there.

Disclaimer: This analysis is for educational purposes only and should not be considered investment advice. Always do your own research before making investment decisions.

Items marked with an asterisk (*) are promotional and help support this newsletter at no cost to readers.

Keep Reading